# Brodalumab Drug-Drug Interaction (DDI) and Intensive Pharmacodynamic (PK) Study in Psoriasis Subjects

> **NCT01937260** · PHASE1 · COMPLETED · sponsor: **Bausch Health Americas, Inc.** · enrollment: 31 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** Brodalumab

## Key facts

- **NCT ID:** NCT01937260
- **Lead sponsor:** Bausch Health Americas, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-09
- **Primary completion:** 2014-07
- **Final completion:** 2014-12
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2017-04-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01937260

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01937260, "Brodalumab Drug-Drug Interaction (DDI) and Intensive Pharmacodynamic (PK) Study in Psoriasis Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01937260. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*